Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 19/20 | 1.00 |
| ▸ | TDO2 | P48775 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20585913 | 1.00 | IDO1 (1.00) | IDO1TDO2POLBHPGD | |
| SCHEMBL2520521 | 0.90 | IDO1 (0.81) | IDO1TDO2POLBHPGD | |
| SCHEMBL2516741 | 0.90 | IDO1 (0.81) | IDO1TDO2POLBHPGD | |
| SCHEMBL2512654 | 0.86 | IDO1 (0.78) | IDO1TDO2POLBHPGD | |
| SCHEMBL149781 | 0.86 | IDO1 (1.00) | IDO1TDO2POLBHPGD | |
| SCHEMBL19808082 | 0.86 | IDO1 (1.00) | IDO1TDO2POLBHPGD | |
| SCHEMBL20585578 | 0.86 | IDO1 (0.75) | IDO1 | |
| SCHEMBL2516041 | 0.85 | IDO1 (0.73) | IDO1TDO2POLBHPGD | |
| SCHEMBL21377764 | 0.85 | IDO1 (0.73) | IDO1TDO2POLBHPGD | |
| SCHEMBL2517466 | 0.84 | IDO1 (0.72) | IDO1TDO2POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192868-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2021-12-07 | — | — | US | claimed |
| US-20190210985-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION | 2019-07-11 | — | — | US | claimed |
| EP-3085697-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Holdings Corporation (US) | 2016-10-26 | — | — | EP | claimed |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2013-05-16 | — | — | US | claimed |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-12-22 | — | — | US | claimed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | claimed |
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE HOLDINGS CORPORATION | 2024-05-30 | — | — | US | disclosed |
| EP-2911669-B1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | UNIV CHICAGO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20220331296-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2022-10-20 | — | — | US | disclosed |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-11192868-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2021-07-29 | — | — | US | disclosed |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | THE UNIVERSITY OF CHICAGO (US) | 2021-04-06 | — | — | US | disclosed |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| US-8034953-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034953-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2315756-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION | 2010-01-21 | — | — | US | disclosed |
| WO-2010005958-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885POLB 2730/4885 |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885POLB 2730/4885 |
| US-11192868-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | IDO1 1/4885TDO2 6/4885POLB 3727/4885 |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885POLB 2730/4885 |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | IDO1 1/4885TDO2 6/4885POLB 3727/4885 |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885TDO2 6/4885POLB 3727/4885 |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | IDO1 3/4885TDO2 78/4885POLB 4503/4885 |
| US-20220331296-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885POLB 2730/4885 |
| US-20190210985-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885TDO2 6/4885POLB 3727/4885 |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | ICOS, IDO1, IL2 | IDO1 2/4885TDO2 115/4885POLB 3342/4885 |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885TDO2 6/4885POLB 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.